Polyglucosamine Adjuvant for STING Pathway Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches, particularly those involving cyclic dinucleotide (CDN) analogues as STING agonists, face challenges in efficacy due to limited cell entry and variable activation across human populations, necessitating the development of a more effective vaccine adjuvant for cGAS-STING pathway activation.
Innovation Solution
The use of polyglucosamine or acetylated polyglucosamine with minimal N-acetyl-D-glucosamine groups, specifically with distributions in blocks of two or more, which efficiently activates the cGAS-STING pathway and promotes anti-tumour immune responses by entering cells and inducing mitochondrial reactive oxygen species, thereby enhancing anti-tumour functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic dinucleotide (CDN) analogues are used as STING agonists, then anti-tumour immune response is activated, but cell entry is limited and activation is variable across human populations
Solution Approach 1:
The patent changes the chemical structure parameters of the adjuvant by using polyglucosamine with specific acetylation patterns (blocks of 2-10 N-acetyl-D-glucosamine groups) instead of conventional CDN analogues. This structural parameter change enables both effective cell entry and reliable STING activation across diverse human populations, resolving the contradiction between activation efficacy and population adaptability.
Solution Approach 2:
The patent employs a composite adjuvant structure combining polyglucosamine backbone with specific acetylated groups arranged in blocks. This composite molecular structure integrates the benefits of both polyglucosamine (cell penetration) and controlled acetylation (STING activation), achieving both reliable pathway activation and broad population adaptability simultaneously.
2Reliability
If highly deacetylated chitosan (polyglucosamine) is used, then anti-tumour functionality is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
Instead of requiring uniform deacetylation throughout the entire polymer chain, the patent applies local quality by allowing specific blocks of acetylated groups (2-10 groups per block) within the polyglucosamine structure. This localized acetylation pattern maintains anti-tumour activity while significantly easing manufacturing precision requirements compared to achieving 90-100% uniform deacetylation.
Solution Approach 2:
The patent applies partial deacetylation (retaining 10-90% acetylation) rather than complete deacetylation. This partial action approach achieves sufficient anti-tumour functionality without the extreme manufacturing precision required for fully deacetylated polyglucosamine, making the therapeutic more manufacturable while maintaining efficacy.
3Reliability
If chitosan with high deacetylation (90-100%) is used, then cellular immune responses are promoted, but the levels of mitochondrial reactive oxygen species are surprisingly elevated causing potential toxicity
Solution Approach 1:
The patent optimizes the deacetylation parameter to a specific range (10-90% acetylation remaining) rather than using extreme high deacetylation. This parameter optimization maintains the ability to promote cellular immune responses while controlling mitochondrial reactive oxygen species levels to prevent toxicity, resolving the contradiction between immune activation and harmful byproduct generation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Polyglucosamine and chitosan, particularly in their highly deacetylated forms, demonstrate potent anti-tumour activity in pre-clinical models, significantly outperforming existing adjuvants by activating immune cells and upregulating checkpoint expression, potentially synergizing with checkpoint inhibitor therapies and inducing direct tumoricidal activity.
Implementation Method 1
the polymer appears to damage the nuclear compartment, allowing the release of nuclear DNA into the cytosol and activating the cGAS-STING pathway
Implementation Method 2
CDNs activate STING, which leads to the expression of potent anti-viral and anti-cancer cytokines that trigger adaptive immunity
Implementation Method 3
the polymer appears to damage the nuclear compartment, allowing the release of nuclear DNA into the cytosol and activating the cGAS-STING pathway
Data Source
AI summary
The invention relates to a method of immunotherapy for prevention or treatment of cancer in a subject, the method comprising the administration of an adjuvant, or administration of an adjuvant in combination with a tumour antigen, to the subject, wherein the adjuvant comprises polyglucosamine or acetylated polyglucosamine that comprises no more than 10% N-acetyl-D-glucosamine groups, and wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of two or more. The invention relates to a method of immunotherapy for solid-tumour cancer in a subject, the method comprising the administration of polyglucosamine or chitosan into the subject, wherein the administration is intratumoral and/or peritumoral.